LONGEVA.

Ipamorelin: adverse events and evidence limits

An intravenous ipamorelin trial after bowel resection lasting up to seven days reported treatment-emergent events. [1]

Its abstract does not establish event-specific frequencies or longer-term risks. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Treatment-emergent adverse eventsPatients after bowel resection, intravenous ipamorelin for up to seven daysReported in the trial; the abstract does not establish event-specific frequencies or longer-term risks[1]

References

  1. David E Beck et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. 10.1007/s00384-014-2030-8.